The in vitro antistaphyococal activity of RP 59500, a new streptogramin, was comparable to those of vancomycin and teliain inst Stqhylcccs aureus, and RP 59 was the most active agent against coagulase-negtive staphylococci. AU staphyococal strains were inhibited by 4 pg of RP 5950 per ml, including multiply resistant strains. Broth microdilution and agar dilution testing gave comparable results in 97% of the tests with RP 59500.
The in vitro antistaphyococal activity of RP 59500, a new streptogramin, was comparable to those of vancomycin and teliain inst Stqhylcccs aureus, and RP 59 was the most active agent against coagulase-negtive staphylococci. AU staphyococal strains were inhibited by 4 pg of RP 5950 per ml, including multiply resistant strains. Broth microdilution and agar dilution testing gave comparable results in 97% of the tests with RP 59500.
RP 59500 is a semisynthetic derivative of pristinamycin, a member of the streptogramin family of antibiotics. Streptogramins are composed of two groups of components; the two main components of pristinamycin are pristinamycin IA, a peptide macrolactone classified as a streptogramin B, and pristinamycm IIA, a polyunsaturated macrolactone classified as a streptogramin A. Both components are water insoluble (2) . RP 59500 methane-sulfonate is a well-defined mixture (IA-IIA, 30:70) of these two pure derivatives which have been chemically modified and are water soluble (1, 2) . The in vitro antimicrobial activity of RP 59500 is similar to that of natural pristinamycin, and its main feature is its activity against methicillin-resistant staphylococci and against macrolide-lincosamide-streptogramin B-resistant gram-positive cocci (MLSB phenotype) (1) . The present study was undertaken to test the in vitro activities of RP 59500 and comparative agents against local strains of staphylococci and to determine whether different testing methods affected these results.
A total of 238 fresh clinical isolates of staphylococci which were isolated from a variety of clinical specimens, including blood, wounds, sputum, intravenous catheter tips, celiulitis, and abscesses, were tested. Of these, 149 were Staphylococcus aureus, as determined by a positive coagulase reaction, and 89 were coagulase-negative staphylococci.
RP 59500 and spiramycin were supplied by Rhone was used for agar dilution testing. Oxacillin susceptibility was tested with each test medium with the addition of 2% NaCl to broth and 4% NaCl to agar. All plates were incubated in ambient air at 35°C for 20 to 24 h and read. The MIC of each antimicrobial agent was defined as the lowest concentration which inhibited the visible growth of the test organism. Table 1 compares the in vitro activities against Staphylococcus species of RP 59500 with those of the other antimicrobial agents as determined by broth microdilution. For S. aureus, 99% of the isolates were inhibited by <1 ,ig of RP 59500 per ml, while a single strain was inhibited by 4 ,ug/ml. Oxacillin-susceptible S. aureus strains were uniformly susceptible to RP 59500, with 100% of the strains inhibited by 1 ,ug/ml. By comparison, RP 59500 was slightly more active than vancomycin and teicoplanin as determined by MICs for 90% of the strains (MIC90s). Against these isolates, erythromycin, spiramycin, and ciprofioxacin were 256-, 16-, and 64-fold less active than RP 59500, respectively.
Strains of oxacillin-resistant S. aureus were highly susceptible (MICg, 1 ,g/ml) to RP 59500, and the activity of RP 59500 was comparable to that of vancomycin and teicoplanin; the MIC90 of all antimicrobial agents was 1 ,ug/ml (Table   1) . Erythromycin, spiramycin, and ciprofioxacin were less active against these strains.
Against coagulase-negative staphylococci, RP 59500 was overall the most active antimicrobial agent tested. For oxacillin-susceptible coagulase-negative staphylococci, the RP 59500 MIC9J was 0.25 ,ug/ml, with the closest comparative agent being ciprofloxacin, with an MIC90 of 0.5 ,ug/ml (Table 1) . Moreover, RP 59500 was 8-, 16-, 32-, and 256-fold more active than vancomycin, spiramycin, teicoplanin, and erythromycin, respectively, by comparison of MIC90s.
Overall, RP 59500 was appreciably more active than the other agents against oxacillin-resistant coagulase-negative staphylococci; only vancomycin showed comparable data.
Strains of S. aureus and coagulase-negative staphylococci which are multiply resistant to oxacillin, erythromycin, and spiramycin were susceptible to RP 59500 (MIC90, 1 ,g/ml).
RP 59500 was slightly more active than vancomycin but appreciably more active than teicoplanin and ciprofloxacin against these strains. Recent pharmacokinetic studies (3) with rabbits receiving RP 59500 (20 mg/kg of body weight) showed average peak levels in plasma of 7.9 jg/ml. These levels are 8-to 32-fold higher than the MIC90s reported here.
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mycin against oxacillin-susceptible and -resistant staphylococci. In that study, the MIC90s of RP 59500 against S.
aureus were virtually identical to ours, even though we tested a larger number of ciprofloxacin-resistant strains. and erythromycin were the antimicrobial agents with the most discrepancies between the two methods. With regard to erythromycin, most MIC discrepancies between the two methods were 23 twofold dilutions; 17 of 19 of these discrepancies were seen with S. aureus strains. The majority of the discrepancies associated with teicoplanin were -2 twofold dilutions. Of 26 discrepancies at c-2 twofold dilutions, 19 were observed with strains of S. aureus, while all 6 discrepancies observed at +2 twofold dilutions were seen with coagulase-negative staphylococci. Of all the compounds tested, only erythromycin showed discrepancies that resulted in changes in susceptibility category. In four instances, organisms were considered moderately susceptible by agar dilution MICs and resistant by broth microdilution MICs; these are considered minor discrepancies.
In summary, our data indicate that RP 59500 exhibits wide-spectrum antistaphylococcal activity against both oxacillin-susceptible and oxacillin-resistant strains. Moreover, RP 59500 was active against strains resistant to erythromycin, spiramycin, and ciprofloxacin. RP 59500 had activity comparable to those of vancomycin and teicoplanin against S. aureus but was more active than both these compounds overall against coagulase-negative staphylococci. RP 59500 warrants further studies to determine the bactericidal potential and the frequency of the development of resistance among staphylococci.
